#Singapore #Aging Research #Immortal Dragons #Etheros

Immortal Dragons Invests in Etheros Pharmaceuticals

In a significant move for the longevity sector, Immortal Dragons, a $40 million innovation fund focused on enhancing life span and health, has announced a strategic investment in Etheros Pharmaceuticals. This research-driven company specializes in developing proprietary water-soluble catalytic antioxidant materials aimed at combating aging-related diseases.

The Role of Oxidative Stress in Aging

As the scientific field dedicated to aging research expands globally, there is a rising interest in investigating the role of reactive oxygen species (ROS) and oxidative stress in biological aging. These ROS are natural by-products of metabolic and inflammatory processes, capable of damaging essential biomolecules. Their accumulation is considered a key factor in age-related biological alterations.

Etheros' innovative materials are set to aid researchers in exploring these oxidative processes more effectively. Previous challenges related to the solubility and performance of fullerene materials will be addressed with Etheros' newly designed catalytic antioxidants.

Innovative Catalytic Antioxidants

Building on decades of research into fullerene science—starting with the landmark discovery of the C60 carbon sphere in 1985, which earned a Nobel Prize in Chemistry in 1996—Etheros has pioneered a new class of water-soluble fullerene derivatives. Unlike traditional forms, which are insoluble in water, these new materials can be utilized for extensive laboratory research.

The company’s derivatives function as catalytic antioxidants, allowing them to continuously neutralize ROS and convert them into more stable molecules without being consumed in the process—a mechanism termed catalytic dismutation. This unique property enables a single fullerene molecule to effectively mitigate large quantities of ROS at elevated reaction rates, promising exciting new pathways for aging-related research.

Foundational Research and Potential

Etheros has diligently worked over the years, publishing research on the behavior of fullerene derivatives under various lab settings and animal models. Observations from their studies have revealed notable effects such as:

• - Modulation of oxidative stress
• - Exploration of neurobiological pathways
• - Changes in behavioral and cognitive performance during aging studies
• - Supportive findings in models relating to neuroinflammation

Importantly, these findings are grounded in research and are not associated with any therapeutic claims or clinical applications. The materials developed by Etheros are intended solely for scientific examination and should not be mistaken for pharmaceutical products.

A Synergistic Partnership

The decision by Immortal Dragons to invest in Etheros aligns with the fund’s mission to explore foundational technologies that illuminate the complexities of aging. According to Dr. Jack Scannell, CEO of Etheros, “Immortal Dragons are both bold and thoughtful—their support has been invaluable as we advance our scientific platform.”
Boyang Wang, founder of Immortal Dragons, remarked on Etheros' unique approach to addressing aging science through catalytic antioxidant materials. He noted, “Their platform aligns strongly with our mission to support pioneering technologies in the longevity field.”

Future Prospects

With this new funding, Etheros plans to enhance its research capabilities by:

• - Optimizing materials for diverse research settings
• - Conducting analytical studies to assess catalytic performance
• - Scaling up their research-grade manufacturing processes
• - Developing biomarkers and analytical tools for laboratory studies

The organization is also laying the groundwork for future regulatory discussions, eyeing potential research pathways that could revolutionize the understanding of aging and oxidative stress, although they are not pursuing any pharmaceutical development or clinical applications at this stage.

About Immortal Dragons

Headquartered in Singapore, Immortal Dragons is dedicated to advancing high-impact scientific initiatives in aging research. They boast a portfolio comprising over 15 companies and are committed to promoting longevity education and scientific dialogue through various platforms. Their recent investment in Etheros signifies a pivotal step forward in the exploration of innovative solutions to age-related challenges, with the potential to greatly enhance our understanding of the aging process.